MedPath
Found 76 clinical trials|View Analysis
Sort by:

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Phase 1
Terminated
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
First Posted Date
2024-10-23
Last Posted Date
2024-10-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
4
Registration Number
NCT06655818
Locations
🇰🇷

GSK Investigational Site, Ulsan, Korea, Republic of

Mezigdomide and Elranatamab for Relapsed And/or Refractory Multiple Myeloma

Phase 1
Recruiting
Conditions
Relapsed Refractory Multiple Myeloma (RRMM)
Interventions
First Posted Date
2024-10-17
Last Posted Date
2024-12-24
Lead Sponsor
YOUNGIL KOH
Target Recruit Count
75
Registration Number
NCT06645678
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1
Recruiting
Conditions
Multiple Myeloma
Interventions
Biological: OL-101 infusion
First Posted Date
2024-10-16
Last Posted Date
2024-11-08
Lead Sponsor
Zhejiang University
Target Recruit Count
58
Registration Number
NCT06644118
Locations
🇨🇳

Beijing Gobroad Boren Hospital, Beijing, Beijing, China

🇨🇳

The Affiliated Hospital of Northwest University Xi'an No.3 Hospital, Xi'an, Shanxi, China

🇨🇳

The first affiliated hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3
Not yet recruiting
Conditions
Relapsed or Refractory Multiple Myeloma (RRMM)
Interventions
First Posted Date
2024-09-26
Last Posted Date
2024-12-20
Lead Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Target Recruit Count
440
Registration Number
NCT06615479
Locations
🇦🇺

Local Institution - 0190, Liverpool, New South Wales, Australia

🇦🇺

Local Institution - 0191, Melbourne, Victoria, Australia

🇺🇸

Local Institution - 0071, Birmingham, Alabama, United States

and more 108 locations

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Phase 1
Recruiting
Conditions
Myeloma
Multiple Myeloma
Refractory Multiple Myeloma
Interventions
First Posted Date
2024-07-24
Last Posted Date
2024-11-20
Lead Sponsor
Omar Nadeem, MD
Target Recruit Count
49
Registration Number
NCT06518551
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Puesta Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1
Not yet recruiting
Conditions
Relapsed or Refractory Multiple Myeloma (RRMM)
Interventions
Drug: Purinostat Mesylate 3mg/m2
Drug: Purinostat Mesylate 4 mg/m2
Drug: Purinostat Mesylate 6 mg/m2
Drug: Purinostat Mesylate 8.4 mg/m2
First Posted Date
2024-07-03
Last Posted Date
2024-07-03
Lead Sponsor
Chengdu Zenitar Biomedical Technology Co., Ltd
Target Recruit Count
126
Registration Number
NCT06484829
Locations
🇨🇳

West China Hospital Sichuan University, Chengdu, Sichuan, China

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

Active, not recruiting
Conditions
Relapsed and Refractory Multiple Myeloma (RRMM)
First Posted Date
2024-06-28
Last Posted Date
2024-10-26
Lead Sponsor
Pfizer
Target Recruit Count
1
Registration Number
NCT06479954
Locations
🇯🇵

Pfizer, Tokyo, Japan

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

First Posted Date
2024-06-18
Last Posted Date
2024-06-18
Lead Sponsor
Nanjing IASO Biotechnology Co., Ltd.
Target Recruit Count
240
Registration Number
NCT06464991
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

🇨🇳

Peking University Third Hospital, Beijing, China

🇨🇳

People's Hospital of Peking University, Beijing, China

and more 23 locations

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Phase 2
Not yet recruiting
Conditions
Refractory Multiple Myeloma
Multiple Myeloma
Cytokine Release Syndrome
Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Drug: Siltuximab
Drug: Teclistamab(FDA-approved)
First Posted Date
2024-04-08
Last Posted Date
2024-08-09
Lead Sponsor
Jack Khouri
Target Recruit Count
20
Registration Number
NCT06352866
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, Cleveland, Ohio, United States

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Phase 1
Not yet recruiting
Conditions
Primary Plasma Cell Leukemia
Multiple Myeloma
Interventions
Biological: CT071
First Posted Date
2024-03-27
Last Posted Date
2024-03-27
Lead Sponsor
CARsgen Therapeutics Co., Ltd.
Target Recruit Count
166
Registration Number
NCT06333509
© Copyright 2025. All Rights Reserved by MedPath